Cargando…

Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients

BACKGROUND AND AIMS: Animal studies suggested that vildagliptin might exert a beneficial effect on cognitive function. The present study evaluated whether the use of vildagliptin in patients with type 2 diabetes mellitus might affect dementia risk. METHODS: The database of Taiwan’s National Health I...

Descripción completa

Detalles Bibliográficos
Autor principal:	Tseng, Chin-Hsiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120263/ https://www.ncbi.nlm.nih.gov/pubmed/33995274 http://dx.doi.org/10.3389/fendo.2021.637392

Ejemplares similares

Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2019)

Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2023)

Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus
por: Tseng, Chin-Hsiao
Publicado: (2020)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study
por: Al-Arouj, M, et al.
Publicado: (2013)

Metformin and the Risk of Dementia in Type 2 Diabetes Patients
por: Chin-Hsiao, Tseng
Publicado: (2019)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study
por: Tseng, Chin-Hsiao
Publicado: (2022)

Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
por: Sridhar, GR, et al.
Publicado: (2023)

Prevalence and Risk Factors of Sensory Symptoms in Diabetes Patients in Taiwan
por: Tseng, Chin-Hsiao, et al.
Publicado: (2021)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
por: Tseng, Chin-Hsiao
Publicado: (2022)

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
por: Gautam, Kumar, et al.
Publicado: (2023)

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)
por: Mathieu, C, et al.
Publicado: (2013)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis
por: Tseng, Chin-Hsiao
Publicado: (2018)

Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone
por: Tseng, Chin-Hsiao
Publicado: (2019)

Human Insulin Therapy Is Associated With an Increased Risk of Lung Cancer: A Population-Based Retrospective Cohort Study
por: Tseng, Chin-Hsiao
Publicado: (2019)

Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
por: Kume, Shinji, et al.
Publicado: (2012)

Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol
por: Yeu, Rui Qian, et al.
Publicado: (2020)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
por: Foley, James E.
Publicado: (2019)

Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial
por: Brandon, Rebecca, et al.
Publicado: (2023)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
por: Pan, CY, et al.
Publicado: (2013)

The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction
por: Trevisan, Roberto
Publicado: (2017)

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
por: van Poppel, Pleun C.M., et al.
Publicado: (2011)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis
por: Mera, Jun-ichiro, et al.
Publicado: (2015)

Pioglitazone and thyroid cancer risk in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2014)

Sitagliptin and oral cancer risk in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2017)

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus
por: Chakraborti, C.K.
Publicado: (2008)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
por: Mathieu, Chantal, et al.
Publicado: (2008)

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Profit, Louise, et al.
Publicado: (2008)

The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects
por: Ito, Daisuke, et al.
Publicado: (2015)

Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study
por: Erande, Suhas, et al.
Publicado: (2023)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Chronic Metformin Therapy is Associated with a Lower Risk of Hemorrhoid in Patients with Type 2 Diabetes Mellitus
por: Tseng, Chin-Hsiao
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1c7kgl6euopovsurb1nphc5sdu